Zymeworks Q3 2024 GAAP EPS $(0.39) Beats $(0.47) Estimate, Sales $16.000M Miss $17.681M Estimate
Portfolio Pulse from Benzinga Newsdesk
Zymeworks reported a Q3 2024 GAAP EPS of $(0.39), beating the estimate of $(0.47), but sales of $16.000M missed the $17.681M estimate. Sales decreased by 3.07% compared to the same period last year.

October 31, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Zymeworks' Q3 2024 earnings per share beat expectations, but sales fell short of estimates and decreased year-over-year.
Zymeworks' better-than-expected EPS suggests cost management or operational efficiency, but the sales miss and year-over-year decline indicate potential challenges in revenue growth. The mixed results may lead to a neutral short-term stock price impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100